Top-line results from KALM-2, the second of two Phase III studies of Cara Therapeutics Inc.'s pruritus therapy, Korsuva (CR845/difelikefalin), have confirmed the efficacy of the intravenous therapy to treat the condition in patients with chronic kidney disease on dialysis.
Results from the first Phase III trial, KALM-1, outlined in May 2019, were favorably received by analysts, who said they...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
